These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24151830)

  • 1. Therapy of H7N9 pneumonia: current perspectives.
    Cao B; Hayden FG
    Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1123-6. PubMed ID: 24151830
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs: Lines of defence.
    Palmer R
    Nature; 2011 Dec; 480(7376):S9-10. PubMed ID: 22158299
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current anti-influenza virus chemotherapy].
    Yoshioka D; Tokimatsu I; Ishii H; Kadota J
    Nihon Rinsho; 2010 Sep; 68(9):1679-84. PubMed ID: 20845747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
    Hu Y; Lu S; Song Z; Wang W; Hao P; Li J; Zhang X; Yen HL; Shi B; Li T; Guan W; Xu L; Liu Y; Wang S; Zhang X; Tian D; Zhu Z; He J; Huang K; Chen H; Zheng L; Li X; Ping J; Kang B; Xi X; Zha L; Li Y; Zhang Z; Peiris M; Yuan Z
    Lancet; 2013 Jun; 381(9885):2273-9. PubMed ID: 23726392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing antiviral therapy for influenza: understanding the evidence.
    Ison MG
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir resistance in influenza A (H5N1) infection.
    Gupta RK; Nguyen-Van-Tam JS
    N Engl J Med; 2006 Mar; 354(13):1423-4; author reply 1423-4. PubMed ID: 16571890
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
    Zhang Y; Gao H; Liang W; Tang L; Yang Y; Wu X; Yu L; Chen P; Zheng S; Ou H; Li L
    BMC Infect Dis; 2016 Feb; 16():76. PubMed ID: 26864456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
    Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to neuraminidase inhibitors.
    Dolin R
    Clin Infect Dis; 2011 Feb; 52(4):438-9. PubMed ID: 21248366
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
    Takemoto Y; Asai T; Ikezoe I; Yano T; Ichikawa M; Miyagawa S; Matsumoto J
    Chemotherapy; 2013; 59(5):373-8. PubMed ID: 24821568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for H5N1: lessons learned from the H1N1 pandemic.
    Reece PA
    Postgrad Med; 2010 Sep; 122(5):134-41. PubMed ID: 20861597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
    Reina J
    Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
    Song JY; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Expert Rev Anti Infect Ther; 2015; 13(11):1361-72. PubMed ID: 26256778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drugs for influenza 2012-2013.
    Med Lett Drugs Ther; 2012 Dec; 54(1405):97-8. PubMed ID: 23223245
    [No Abstract]   [Full Text] [Related]  

  • 17. Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan.
    Lin PH; Chao TL; Kuo SW; Wang JT; Hung CC; Lin HC; Yang ZY; Ho SY; Chang CK; Huang MS; Chen HH; Chen YC; Lai HS; Chang SY; Chang SC; Yang PC
    Clin Infect Dis; 2014 Jan; 58(2):242-6. PubMed ID: 24076969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress of neuraminidase inhibitors for anti-influenza].
    Liu AL; Wang HD; Yang F; Du GH
    Yao Xue Xue Bao; 2009 Sep; 44(9):935-42. PubMed ID: 20055166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral drugs for influenza.
    Med Lett Drugs Ther; 2008 Dec 15-29; 50(1301-1302):98-9, 104; quiz p following 104. PubMed ID: 19078865
    [No Abstract]   [Full Text] [Related]  

  • 20. Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
    Woods CJ; Malaisree M; Long B; McIntosh-Smith S; Mulholland AJ
    Sci Rep; 2013 Dec; 3():3561. PubMed ID: 24356381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.